Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets ...

Wegovy maker’s share price halves amid rising pressure from Eli Lilly and compounded copycats Novo Nordisk has removed its long-serving CEO, Lars Fruergaard Jørgensen, as the Danish pharmaceutical ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

The pharmaceutical giant Novo Nordisk announced on Friday, May 16, 2025, that CEO Lars Fruergaard Jørgensen is stepping down amid mounting challenges for the obesity drug maker. The sudden leadership ...